We reported earlier the discovery of 1 (FR 193108) 1,2) as a dual CCK-A and -B antagonist, according to our hypothesis that a dual CCK-A and CCK-B antagonist is more efficacious for the treatment of pancreatitis than a CCK-A selective antagonist.
I-CCK-8 binding to the CCK-B receptor. As a result of our studies, we have now discovered 40, which showed higher affinity than 35 for the CCK-B receptor and was almost equal for the CCK-A receptor as 35.
The optically active enantiomers of 40 were prepared via an optical resolution of the 3-amino intermediate. The 3R-isomer, (R)-40 (FR208419), is now undergoing further biological evaluation with a view to clinical development.
The design leading to (R)-40, has been outlined in a review. 4) In this paper we describe in full the synthesis and structure-activity relationships of (R)-40 and its related compounds.
Chemistry
A very convenient method for building the 1,4-benzodiazepine nucleus was reported by Sherrill 5) employing the reagent 2-(benzotriazol-1-yl)-N-protected glycine. This method was applied to the preparation of our key intermediate 3-benzyloxycarbonyl-5-alkyl-9-methyl-1,4-benzodiazepines (4a-i) and the target compounds (7) (8) (9) (10) (11) (12) (13) (14) were synthesized as shown in Chart 1.
o-Toluidine (2) was regioselectively acylated by the Suga-sawa reaction; 6) 2-methyl-6-(4Ј-chlorobutanoyl)aniline was obtained in the case employing cyclopropylcyanide as the acylating reagent under the Sugasawa reaction. However, this was transformed to the desired 2-cyclopropanoyl-6-methylaniline (3e) by treatment with potassium tert-butoxide. 7) 2-Chloroacetyl-6-methylaniline (3g), obtained from o-toluidine (2) and chloroacetonitrile, was converted to 2-methoxyacetyl and 2-dimethylaminoacetyl aniline derivatives (3h and 3i) by treatment with sodium methoxide and dimethylamine, respectively. These 2-acyl-6-methylaniline derivatives were easily acylated with the acid chloride, prepared from Sherrill's reagent, 2-(benzotriazol-1-yl)-N-benzyloxy-carbonyl glycine, and oxalyl chloride in situ, in the presence of Nmethylmorpholine. The acylated compounds were treated, without isolation, with saturated methanolic ammonia followed by cyclization with ammonium acetate in acetic acid at ambient temperature to afford 5-alkyl-9-methyl-3-benzyloxycarbonylamino-1,4-benzodiazepine nuclei (4a-i) in moderate yields. The intermediates 6-1 (a-i) were prepared by alkylation at N-1 position of (4a-i) with ethyl bromoacetate in the presence of sodium hydride, followed by alkaline hydrolysis and amidation with 3-azabicyclo[3.2.2]nonane in a procedure similar to that reported in our previous paper. 1) The benzyloxycarbonyl group of 6-1 was removed by hydrogenolysis using ammonium formate and 10% palladium on carbon in ethanol at ambient temperature. The obtained 3-amino intermediates were then acylated with m-tolyl isocyanate to give the initially targeted compounds 7-14.
5-Acetoxymethyl-, 5-hydroxymethyl-, and 5-methylthiomethyl-1,4-benzodiazepines (16, 17 and 18) were prepared as follows; treatment of 7 with m-chloroperbenzoic acid in methylene chloride afforded N-4 oxide (15), which could be transformed to 16 by treatment with acetic anhydride and was followed by alkaline hydrolysis to give 17. Mesylation of 17 and displacement with sodium methylmercaptide afforded 18, as shown in Chart 2. The yields and physical data of 7-18 are summarized in Table 1 and those of their intermediates are described in the Experimental.
We also installed other types of amide and ketones as N-1 side chain to the 5,9-dimethyl-1,4-benzodiazepine ring system in order to avoid the bulky 3-azabicyclo[3.2.2]nonanyl amide as shown in Chart 3.
3-Benzyloxycarbonylamino-5,9-dimethyl-2-oxo-1,4-benzodiazepine (4a) was deprotected by hydrogenolysis to afford the 3-amino derivative (19), which was acylated with m-tolyl isocyanate to afford an N-1-unsubstituted urea (20) . Acetic acid at N-1 (22) was prepared via its ethyl ester (21) in a sim- ilar procedure to those carried out in the synthesis of 5-1 and 5-2, described above. The target amides (26-32) were prepared from 22 by standard amidation using N-ethyl-NЈ-dimethylaminopropylcarbodiimide (WSCD) in the presence of 1-hydroxybenzotriazole (HOBT). The target ketones (35, 37) were synthesized by direct N-1 alkylation of 4a with 1-bromo-3,3-dimethyl-2-oxobutane or bromoacetylcyclohexane in the presence of sodium hydride, followed by deprotection and acylation with m-tolyl isocyanate. The intermediates 24b, d, e were prepared by amidation of N-1-acetic acid 5-2a with N-methyl-N-(2-pyridyl)amine to give the activated amide 23, which was easily reacted with the respective Grignard reagents. The deprotection and acylation were performed as described above to give the target ketones 34, 36, and 37. The yields and physical data of 26-37 are summarized in Table 2 and those of their intermediates are described in the Experimental.
Finally, we introduced other lower alkyl groups excluding a methyl group into the 5 position of the 1-cyclohexylcarbonylmethyl-9-methyl-1,4-benzodiazepine nucleus. Alkylation of 4b-e with bromomethylcyclohexylketone in the presence of sodium hydride afforded 38a-d in a similar manner to that carried out in the preparation of 24c from 4a. Deprotection of 38a-d by hydrogenolysis with ammonium formate and 10% palladium on carbon in ethanol gave 39a-d. The target compounds (40-43) were prepared by a similar acylation with m-tolyl isocyanate as shown in Chart 4 and their yields and physical data are summarized in Table 3 and their intermediates are described in the Experimental.
Biological Evaluation The biological evaluation was performed by means of the following tests 8) : i) inhibition of 125 I-CCK-8 binding in the guinea-pig cerebral cortex, ii) inhibition of 125 I-CCK-8 binding in the rat pancreas, iii) the ratio of the respective IC 50 values, and iv) gastric emptying effect in mice after p.o. administration in vivo, 9) for compounds showing high affinity for both CCK-A and CCK-B receptors. The results are summarized in Tables 4, 5, and 6 for compounds 7-18, possessing various C-5 alkyl substituents in N-1-3-azabicyclo[3.2.2]nonanylcarbonylmethyl-9-methyl-1,4-benzodiazepines, for 26-37, substituted by other types of amides and ketones as N-1 side chain in 5,9-dimethyl-1,4-benzodiazepines, and for 40-43, containing other lower alkyl groups as C-5 substituents in 1-cyclohexylcarbonylmethyl-9-methyl-1,4-benzodiazepines, respectively along with respective reference compounds 1 in Table 4 , 7 in Table 5 , and 35 in Table 6 .
In the N-1-3-azabicyclo[3.2.2]nonanylcarbonylmethyl-9-methyl-1,4-benzodiazepine ring system (Table 4) , the introduction of lower alkyl groups (7) (8) (9) (10) in the 5 position instead of the 2-fluorophenyl group increased the affinity for the CCK-A receptor by 3-to 6-fold, whereas the affinity for the CCK-B receptor was maintained or slightly reduced. Thus, the ratio of IC 50 values to the CCK-A to CCK-B receptors approached unity. A cyclohexyl group was not suitable for the 5 position substituent of this ring system. A methoxymethyl and a methylthiomethyl group were effective substituents, whereas a dimethylaminomethyl group was not suitable as shown by 13, 14 and 18. An acetoxymethyl group was also effective as shown by 16, but a hydroxymethyl group reversed the affinity for the CCK-A and CCK-B receptors and the ratio of them for 17 was 0.2. When considering 7, 13 and 17, it seemed that the hydroxy group of 17 possibly had some contribution to binding affinity for the CCK-A receptor. Methylthio derivative 18 had high affinity for both CCK-A and CCK-B receptors, and the value of the two affinities was close. Potent compounds were evaluated by the gastric emptying test in mice after oral administration. However, their biological activity after p.o. administration was only slightly improved, as shown in Table 4 . We selected a methyl group as the substituent in the 5 position of the 1,4-benzodiazepine nucleus for further optimization research on the N-1 side chain.
Other types of amides and ketones containing a certain degree of bulkiness, which is thought to be necessary to maintain the potent activities, as N-1 side chain in 5,9-dimethyl-1,4-benzodiazepines, are summarized in Table 5 . Acyclic and 5-to 6-membered cyclic amides were found to have reduced affinity for the CCK-B receptor (26-30). However, com-pounds 31 and 32, which have 7-and 8-membered cyclic amides, showed high affinity for both receptors. The affinity for the CCK-B receptor is higher for the larger ring size (28, 30, 31 and 32), but the affinity for the CCK-A receptor is reversed in the 7-and 8-membered rings. Therefore, the ratio of IC 50 values for 31 and 32 were 0.53 and 1.62, respectively. When compared with compound 7, selected as a reference for further optimization, 31 and 32 were as potent for CCK-A receptor binding but decreased in the affinity for the CCK-B receptor by 3-to 5-fold. It was an additional disadvantage that they had poor activities in the gastric emptying after p.o. administration.
On the other hand, compounds 33-37, which contain certain bulky ketones as the N-1 side chain, showed 5-to 20-fold more potent effects than compound 7 on gastric emptying, although their affinities for the CCK-B receptor dimin- ished by 5-to 15-fold, when compared with 7. The compounds with a 6-or 7-membered cycloalkyl methyl ketone were found to be the most suitable for the N-1 side chain. Compounds 35 and 36 showed almost equal high affinity for both receptors, but 35 showed more potent activity in gastric emptying than 36. We selected 35 as a lead compound for further chemical modification in searching for a suitable alkyl group for the 5-substutuent on the 5-alkyl-1-cyclohexylcarbonylmethyl-9-methyl-1,4-benzodiazepine. Ethyl, isopropyl, isobutyl and cyclopropyl groups were introduced at the 5 position, respectively (Table 6 ), however a cyclohexyl group was excluded because of its poor activity in our ring system as shown in Table 4 . When compared with 35, the affinities of compounds 40, 42, and 43 for the CCK-B receptor were increased 2-to 3-fold except for 41, whereas the affinity for the CCK-A receptor was nearly equal or only slightly reduced. Furthermore, the ratio of IC 50 values for CCK-A to CCK-B receptors was Ͻ1.0 for 40 and 41 and Ͼ1.0 for 42 and 43. It was found that compound 40 was as potent as 35 in the gastric emptying effect after p.o. administration, while those of compounds 41, 42, and 43 decreased by 4-to 14-fold.
From all compounds prepared, we selected 40 due to its high and well-balanced affinity for both CCK-A and CCK-B receptors and its good activity after p.o. administration.
Optical Resolution of 40 and Biological Evaluation of the Enantiomers Initially, optical resolution of (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-5-ethyl-9-methyl-1,4-benzodiazepine-2-one (39a) was attempted by classical diastereomeric salt formation with a suitable optically active acid. Unfortunately, crystalline salt formation was unsuccessful, despite many trials with a variety of optically active acids, solvents and their combinations. However we did succeed in the optical resolution by the method 10) of diastereoisomers formation with L-phenylalanine, followed by their separation by column chromatography and Edman 6 Vol. 48, No. 1 Table 3 . Yield, Physical, and Spectral Data of Compounds 40-43 Table 4 .
chloroform and methanol (20 : 1). Each diastereoisomer (S)-45 and (R)-45 was then degraded under Edman reaction conditions to afford the 3-amino enantiomers (S)-39a and (R)-39a. This method was not practical for large scale preparation since it contains a separation process via column chromatography, but it does afford sufficient quantities and purities for full assignment of stereostructure and assessment of biological activities. The purities and absolute configuration of these enantiomers (S)-39a and (R)-39a were determined by 1 H-NMR spectra and X-ray crystallographical analysis of their ureido derivatives formed with (S)-(Ϫ)-a-methylbenzyl isocyanate, respectively. The more polar diastereoisomer of the L-phenylalanylamide separated by column chromatography was degraded to the amine followed by reaction with (S)-(Ϫ)-a-methylbenzyl isocyanate and recrystallization to afford colorless prisms from a mixture of diisopropyl ether and methanol. An X-ray crystallographical analysis confirmed that the afforded prismatic crystals were (3S)-1-cyclohexylcarbonylmethyl-5-ethyl-3-[(S)-a -methylbenzylureido]-9-methyl-1,4-benzodiazepin-2-one (46) (Fig. 2) .
Thus, the optically active 3-amino intermediate obtained by Edman degradation from the more polar diastereoisomer was determined to be the (3S)-isomer, (S)-39a, and from the less polar diastereomer to be the (3R)-isomer, (R)-39a.
The target m-tolyl ureas (S)-40 and (R)-40 were prepared from these optically active amines by reaction with m-tolyl isocyanate without stereoinversion. The enantiomer excesses of the target compounds were determined to be 97.0% and 98.7%, respectively, by high-performance liquid chromatography (HPLC) with a chiral stationary-phase column (CHI-RALCEL OD). Their biological activities are shown in Table  7 along with those of the parent racemate.
The R-enantiomer, (R)-40, was found to have higher affinity for both CCK-A and -B receptors and to be 27-fold higher for CCK-A receptor affinity and 8-fold more potent in CCK-B receptor binding activity than (S)-40. The selectivity (A/B) of (R)-40 was found to be 0.30.
The activity after p.o. administration of (R)-40 is considered to be high enough for further development, which was estimated from the ID 50 value obtained by preliminary evaluation of gastric emptying effects.
This final compound, (R)-40 (FR208419), is now undergoing further research for a practical method of optical resolution and further pharmaceutical evaluations with a view to clinical development.
Conclusion
In our continuing research for dual CCK-A and -B antagonists according to our hypothesis that dual CCK-A and -B antagonists should be more efficacious than selective CCK-A antagonists for the treatment of pancreatitis, we have prepared various 5-alkyl-9-methyl-1,4-benzodiazepines. Of all compounds prepared, 1-cyclohexylcarbonyl-methyl-5-ethyl-9-methyl-3-(m-tolylureido)-2-oxo-1,4-benzodiazepine, 40, was 8 Vol. 48, No. 1 Table 4 . selected as a candidate compound due to its well-balanced high affinity for both receptors. The R-enantiomer, (R)-40, was found to have higher affinities for both CCK-A and -B receptors than (S)-40. The selectivity (A/B) of (R)-40 was found to be 0.30. The activity after p.o. administration of (R)-40, estimated from the ID 50 value (0.23 mg/kg p.o.) obtained by preliminary evaluation by gastric emptying effects, is considered to be high enough for further development. This compound is now undergoing further biological evaluations with a view to clinical development.
Experimental
Melting points were determined on a BÜCHI 535 meltemp apparatus and are uncorrected. IR spectra were recorded on a Shimazu IR-408 spectrometer.
1 H-NMR (200 MHz) spectra were performed on a Bruker AC 200 P instrument, using tetramethylsilane (TMS) as an internal standard. Mass spectra were measured on an atmospheric pressure ionization HITACHI M-1000 mass instrument. Optical rotations were determined with a JASCO DIP-360. Elemental analyses were within Ϯ0.4% of the theoretical values for elements indicated unless otherwise noted. The yields reported are not optimized.
2-Acetyl-6-methylaniline (3a) To a solution of o-toluidine (2) (32.8 g, 0.3 mol) and acetonitrile (6.22 g, 0.15 mol) in toluene (200 ml) was added dropwise 1 M-borontrichloride toluene solution (150 ml) with stirring and cooling in an ice bath below 5°C. After the addition was completed, the mixture was stirred at ambient temperature for 1 h. The mixture was cooled again and aluminum chloride (20.0 g, 0.15 mol) was added portionwise. The resultant mixture was gradually warmed and refluxed for 5 h. The reaction mixture was cooled in an ice bath and 2 N aqueous hydrochloric acid (200 ml) was added dropwise under stirring. The mixture was refluxed for 2.5 h. The reaction mixture was cooled to ambient temperature and extracted with ethyl acetate. The organic extract was washed with water twice and brine, successively, and dried over magnesium sulfate. Removal of the solvent in vacuo gave crystals, which were washed with hexane and collected by filtration to give 3a (8. 2-Cyclopropylcarbonyl-6-methylaniline (3e) A mixture of 2-(4-chlorobutanoyl)-6-methylaniline (538 mg, 2.54 mmol), obtained in a similar procedue to that carried out in the preparation of 3a with cyclopropyl cyanide instead of acetonitrile, and potassium tert-butoxide (285 mg, 2.54 mmol) in tetrahydrofuran (8 ml) was stirred at ambient temperature for 1.5 h. Ethyl acetate and 0.1 N aqueous hydrochloric acid were added to the reaction mixture. The separated organic layer was washed with water, saturated aqueous sodium bicarbonate and brine, successively, and dried over magnesium sulfate. Removal of the solvent in vacuo afforded 3e as an amorphous powder (445 mg, 100% 2-Methoxyacetyl-6-methylaniline (3h) To a solution of 3g (1.84 g, 10 mmol) in methanol (50 ml) was added 28% methanolic sodium methoxide (5.79 g, 10.0 mmol) with stirring and cooling in an ice-bath. The mixture was stirred for 0.5 h, and then at ambient temperature overnight. Methanol was removed in vacuo. The residue was dissolved in ethyl acetate and washed with water and brine successively. The organic layer was dried over magnesium sulfate and evaporated in vacuo to give an oil, which was subjected to column chromatography on silica gel eluting with chloroform. The fractions containing the desired product were combined and evaporated to give 3h as an oil (1.07 g, 59.7% zotriazol-1-yl)glycine (14.11 g, 43 mmol) in dry tetrahydrofuran (100 ml) was added oxalyl chloride (3.77 ml, 43 mmol) and dimethylformamide (3 drops) with stirring at 0°C in an ice-salt bath under a nitrogen stream. After the mixture was stirred at the same temperature for 2 h, a mixture of 3a (4.30 g, 29 mmol) and N-methylmorpholine (8.74 g, 86 mmol) in tetrahydrofuran (20 ml) was added dropwise over a period of 20 min. After the addition was completed, the mixture was allowed to warm to ambient temperature with stirring. Tetrahydrofuran was removed in vacuo and the residue was dissolved in ethyl acetate. The mixture was washed with water twice and dried over magnesium sulfate. Removal of the solvent gave an intermediate product as an oil, to which was added 20% methanolic ammonia (75 ml) and stirred at ambient temperature overnight. The resultant precipitate was collected by filtration and washed with cold methanol and diisopropyl ether successively and dried to give 4a as a white crystalline powder (6.17 g, 63.5%), mp 238.0-239.5°C. 02 (2H, br), 7.1-7.5 (6H, m), 7.6-7.8 (1H, m) (3RS)-3-Benzyloxycarbonylamino-2,3-dihydro-5-methoxy-methyl-9-methyl-1H-1,4-benzodiazepin-2-one (4h (3RS)-3-Benzyloxycarbonylamino-2,3-dihydro-5-dimethylaminomethyl-9-methyl-1H-1,4-benzodiazepin-2-one (4i 3RS)-3-Benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1-ethoxycarbonylmethyl-1H-1,4-benzodiazepin-2-one (5-1a) A mixture of 4a (1.0 g, 2.96 mmol) and 60% sodium hydride (120 mg, 3 mmol) in dimethylformamide (10 ml) was stirred at 0°C for 1 h and at ambient temperature for 3 h. To the resultant mixture was added dropwise ethyl bromoacetate (476 mg, 2.96 mmol) under cooling at 5°C in an ice bath. The mixture was stirred at ambient temperature for 5.5 h. The reaction mixture was poured into 0.1 N aqueous hydrochloric acid and extracted with ethyl acetate. The extract was washed with water twice, saturated aqueous sodium bicarbonate and brine, successively, and dried over magnesium sulfate. The solvent was removed in vacuo to afford 5-1a as an oil (1.25 g, 100%). (3RS)-3-Benzyloxycarbonylamino-2,3-dihydro-1-ethoxy-carbonyl-methyl-5-methoxymethyl-9-methyl-1H-1,4-benzodiazepin-2-one (5-1h (3RS)-3-Benzyloxycarbonylamino-1-carboxymethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (5-2a) A mixture of 5-1a (1.25 g, 2.96 mmol) and 1 N aqueous sodium hydroxide (7.0 ml) in dimethoxyethane (DME, 10 ml) was stirred at ambient temperature overnight. The reaction mixture was evaporated in vacuo, and the residue was dissolved in a mixture of ethyl acetate and 1 N aqueous hydrochloric acid. The separated organic layer was washed with water and brine, and dried over magnesium sulfate. The solvent was evaporated in vacuo, and the residue was triturated with diisopropyl ether and collected by filtration to give 5-2a (985 mg, 84.2%) as a white crystalline powder, mp 188.7-190.2°C. (3RS)-1-(3-Azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-3-benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one  (6-1a) 1-(3-Azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-3-benzyloxycarbonylamino-5-cyclohexyl-2,3-dihydro-9-methyl-1H-1,4 -benzodiazepin-2-one (6-1f) Yield 100%. 1-(3-Azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-3-benzyloxycarbonylamino-2,3-dihydro-5-methoxymethyl-9-methyl-1H-1,4-benzodiazepin-2-one (6-1h) Yield 82.5%. (3RS)-3-Amino-1-(3-azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (6-2a) A mixture of 6-1a (999 mg, 1.93 mmol), 10% palladium on carbon (50% wet, 250 mg) and ammonium formate (600 mg, 9.5 mmol) in ethanol (15 ml) was stirred at ambient temperature for 1 h. The catalyst was filtered off and the filtrate was evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate, water, and brine successively. After drying over sodium sulfate, the solvent was evaporated in vacuo, and the residue was triturated in diisopropyl ether and collected by filtration to give 6-2a (644 mg, 87.0%) as an amorphous mass.
1 H-NMR (CDCl 3 ) d: 1.27 (3H, t, Jϭ7.3 Hz), 1.5- 1.8 (8H, m), 1.8-2.1 (2H, m), 2.35 (3H, s),  2.89 (2H, q, Jϭ7.3 Hz), 3.3-3.4 (2H, m), 3.5-3.6 (2H, m) (3RS)-3-Amino-1-(3-azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-5-isopropyl-9-methyl-1H-1,4-benzodiazepin-2-one (6-2c) Yield 69.8%. mp 169.1-163.5°C. Other target compounds 8-14 were obtained in a similar procedure to that carried out in the preparation of 7. Physical and spectral data of these compounds (7) (8) (9) (10) (11) (12) (13) (14) are summarized in Table 1 . After stirring for 5.5 h, additional m-CPBA (48 mg) was added and the stirring was continued for a further 3.5 h. Methylene chloride was removed in vacuo to give a residue, which was dissolved in ethyl acetate and washed with an aqueous solution of sodium bicarbonate, water and brine successively. The organic layer was dried over magnesium sulfate and evaporated in vacuo to afford a reddish oil, which was subjected to preparative thin layer chromatography on silica gel developed with a mixture of chloroform and methanol (10 : 1) to give 15 as a white crystalline powder (65.5 mg, 48.0%), mp 242.4-244.6°C. N-[(3RS)-5-Acetoxymethyl-1-(3-azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-9-methyl-1H-1,4-benzodiazepin-2-one-3-yl]-N-(3-methylphenyl)urea (16) A mixture of 15 (45.3 mg, 0 .088 mmol) and acetic anhydride (1.8 ml) was stirred at 50°C for 5 h. After the reaction was completed, acetic anhydride was removed under reduced pressure. The residue was subjected to preparative thin layer chromatography on silica gel developed with a mixture of chloroform, ethyl acetate and methanol (14 : 1 : 0.4) to give 16 as an amorphous powder, which was triturated in diisopropyl ether and collected by filtration (26.5 mg, 59.3%). Physical and spectral data of this compound are summarized in Table 1 . .37 mmol) in ethanol (4 ml) was added 1 N aqueous sodium hydroxide (1 ml) under stirring at ambient temperature. The mixture was stirred for 20 min under the same conditions. After removal of the solvent, water was added to the mixture, which was adjusted to pH 4 with diluted hydrochloric acid and extracted with ethyl acetate twice. The combined extract was washed with water and dried over magnesium sulfate. Removal of the solvent gave an amorphous powder, which was triturated in diisopropyl ether to afford 17 (127 mg, 66.0%) as an amorphous powder. Physical and spectral data of this compound are summarized in Table 1 .
N-[(3RS)-1-(3-Azabicyclo[3.2.2]nonan-3-yl)carbonylmethyl-2,3-dihydro-9-methyl-5-methylthiomethyl-1H-1,4-benzodiazepin-2-one-3-yl]-N-(3-methylphenyl)urea (18)
To a mixture of 17 (147 mg, 0.28 mmol) and diisopropylethylamine (55.1 mg, 0.43 mmol) in methylene chloride (2 ml) was added dropwise a solution of methanesulfonyl chloride (48.7 mg, 0.43 mmol) in methylene chloride (1 ml) under stirring and cooling at 5°C in an ice-bath. The mixture was stirred for 1.5 h under the same conditions. The reaction mixture was evaporated in vacuo. The residue was dissolved in tetrahydrofuran (2 ml) and cooled in an ice-bath. To the solution obtained above was added 15% aqueous solution of sodium methanethiolate (0.5 g). The mixture was stirred under cooling for 0.5 h and at ambient temperature for 2 h. The reaction mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with water twice. The separated organic layer was dried over magnesium sulfate and evaporated in vacuo to afford an amorphous mass, which was subjected to preparative thin layer chromatography on silica gel developing with a mixture of chloroform and methanol (10 : 1) to give 18 as an amorphous mass. This was triturated in diisopropyl ether and collected by filtration to give a crystalline powder (71.9 mg, 46.2%). Physical and spectral data of this compound are summarized in Table 1 .
(3RS)-3-Amino-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (19) The title compound was obtained in a similar procedure to that carried out in the preparation of 6-2a as a white crystalline powder (yield 59.3%), mp 166.6-168.0°C. N-[(3RS)-1-Carboxymethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one-3-yl]-N-(3-methylphenyl) N-(3RS)-3-Benzyloxycarbonylamino-2,3-dihydro-5,9-dimethyl-1-[Nmethyl-N-(2-pyridyl)amino]carbonylmethyl-1H-1,4-benzodiazepin-2-one (23) A mixture of 5-2a (3.26 g), N-ethyl-NЈ-(3-dimethylaminopropyl) N-(3RS)-3-Benzyloxycarbonylamino-1-cycloheptylcarbonylmethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (24d) The title compound was obtained in a similar procedure to that carried out in the preparation of 24b using cycloheptyl magnesium bromide instead of cyclopentyl magnesium chloride (yield 80.4%). N-(3RS)-3-Benzyloxycarbonylamino-1-cyclooctylcarbonylmethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (24e) The title compound was obtained in a similar procedure to that carried out in the preparation of 24b using cyclooctyl magnesium bromide instead of cyclopentyl magnesium chloride (yield 67.4%). N-(3RS)-3-Amino-1-(1,1-dimethylethyl) carbonylmethyl-2,3-dihydro-5,9-dimethyl-1H-1,4-benzodiazepin-2-one (25a) The title compound was obtained in a similar procedure to that carried out in the preparation of 6-2a as a white amorphous powder (yield 80.3% The target compounds 26-32 were obtained in a similar procedure to that carried out in the preparation of 6-1a. The target compounds 33-37 were obtained in a similar procedure to that carried out in the preparation of 7. Physical and spectral data of 26-37 are summarized in Table 2 .
(3RS)-3-Benzyloxycarbonylamino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one (38a) The title compound was obtained in a similar procedure to that carried out in the preparation of 24c as a white crystalline powder (yield 41.2%), mp 74.1-76.8°C. 
